United Therapeutics Chairperson, CEO Martine Rothblatt reports sale of 9,500 shares worth $5.22 million

United Therapeutics Corporation

United Therapeutics Corporation

UTHR

0.00
  • United Therapeutics Chairperson and CEO Martine A. Rothblatt exercised stock options for 9,500 shares at $135.42 on June 25.
  • Rothblatt sold 9,500 shares on June 25 at weighted-average prices ranging from $543.54 to $554.84.
  • Directly held common stock ended the day at 40,513 shares, down from 50,013 shares before the sales.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. United Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001106578-26-000086), on June 26, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.